Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca\(^{2+}\)], Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity

Sylvia Fitting\(^*\),1,5, Sheping Zou\(^2\), Nazira El-Hage\(^1,6\), Masami Suzuki\(^1,7\), Jason J. Paris\(^1\), Christina J. Schier\(^1\), José W. Rodriguez\(^3\), Myosotys Rodriguez\(^3\), Pamela E. Knapp\(^1,2,4\) and Kurt F. Hauser\(^1,4\)

\(^1\)Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0613, USA; \(^2\)Department of Anatomy and Neurobiology, Virginia Commonwealth University School of Medicine, VA 23298-0709, USA; \(^3\)Microbiology and Immunology Department, Universidad Central del Caribe, Bayamón, Puerto Rico, 00960-6032; \(^4\)Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23298-0310, USA; \(^5\)Now at the Department of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3520, USA; \(^6\)Now at the Department of Immunology, Florida International University, Miami, FL 33199, USA; \(^7\)Now at the Cancer Pathophysiology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan

Abstract: Few preclinical studies have compared the relative therapeutic efficacy of medications used to treat opiate addiction in relation to neuroAIDS. Here we compare the ability of methadone and buprenorphine, and the prototypic opiate morphine, to potentiate the neurotoxic and proinflammatory ([Ca\(^{2+}\)], ROS, H\(_2\)O\(_2\), chemokines) effects of HIV-1 Tat in neuronal and/or mixed-glial co-cultures. Repeated observations of neurons during 48 h exposure to combinations of Tat, equimolar concentrations (500 nM) of morphine, methadone, or buprenorphine exacerbated neurotoxicity significantly above levels seen with Tat alone. Buprenorphine alone displayed marked neurotoxicity at 500 nM, prompting additional studies of its neurotoxic effects at 5 nM and 50 nM concentrations ± Tat. In combination with Tat, buprenorphine displayed paradoxical, concentration-dependent, neurotoxic and neuroprotective actions. Buprenorphine neurotoxicity coincided with marked elevations in [Ca\(^{2+}\)], but not increases in glial ROS or chemokine release. Tat by itself elevated the production of CCL5/RANTES, CCL4/MIP-1\(β\), and CCL2/MCP-1. Methadone and buprenorphine alone had no effect, but methadone interacted with Tat to further increase production of CCL5/RANTES. In combination with Tat, all drugs significantly increased glial [Ca\(^{2+}\)], but ROS was only significantly increased by co-exposure with morphine. Taken together, the increases in glial [Ca\(^{2+}\)], ROS, and neuroinflammatory chemokines were not especially accurate predictors of neurotoxicity. Despite similarities, opiates displayed differences in their neurotoxic and neuroinflammatory interactions with Tat. Buprenorphine, in particular, was partially neuroprotective at a low concentration, which may result from its unique pharmacological profile at multiple opioid receptors. Overall, the results reveal differences among addiction medications that may impact neuroAIDS.

Keywords: Calcium, chemokines, buprenorphine, methadone, morphine, neuro-acquired immunodeficiency syndrome (neuroAIDS), opioid drug abuse, oxidative stress.

INTRODUCTION

Evidence suggests that the severity of neuroAIDS may be markedly exacerbated by chronic opiate drug use. The functional impairment associated with neuroAIDS is underscored by synaptic pruning and neuronal injury [1, 2] and is secondary to an infection that is largely restricted to glia and perivascular macrophages [3-8]. Human immunodeficiency virus type 1 (HIV-1) proteins, such as glycoprotein 120 (gp120) and transactivator of transcription (Tat), are released by infected glia have been implicated as possible mediators of neurotoxicity [9-12] and contribute to the release of glial-derived cellular toxins, including reactive oxygen species (ROS) [13-15], calcium overload [16], and chemokines such as CCL5/RANTES, TNF-\(α\), IL-6, CCL4/MIP-1\(β\), and CCL2/MCP-1 [17-24]. Opiates can exacerbate synaptodendritic damage caused by Tat [25, 26] or HIV-1 [27], and significant aspects of the morphine and HIV-1/Tat interactive neurotoxicity are mediated by glia [27, 28]. Opiates exacerbate the neurotoxic and neuroinflammatory chemokine production and correlative neurotoxicity significantly above levels seen with Tat alone. Buprenorphine alone displayed marked neurotoxicity at 500 nM, prompting additional studies of its neurotoxic effects at 5 nM and 50 nM concentrations ± Tat. In combination with Tat, buprenorphine displayed paradoxical, concentration-dependent, neurotoxic and neuroprotective actions. Buprenorphine neurotoxicity coincided with marked elevations in [Ca\(^{2+}\)], but not increases in glial ROS or chemokine release. Tat by itself elevated the production of CCL5/RANTES, CCL4/MIP-1\(β\), and CCL2/MCP-1. Methadone and buprenorphine alone had no effect, but methadone interacted with Tat to further increase production of CCL5/RANTES. In combination with Tat, all drugs significantly increased glial [Ca\(^{2+}\)], but ROS was only significantly increased by co-exposure with morphine. Taken together, the increases in glial [Ca\(^{2+}\)], ROS, and neuroinflammatory chemokines were not especially accurate predictors of neurotoxicity. Despite similarities, opiates displayed differences in their neurotoxic and neuroinflammatory interactions with Tat. Buprenorphine, in particular, was partially neuroprotective at a low concentration, which may result from its unique pharmacological profile at multiple opioid receptors. Overall, the results reveal differences among addiction medications that may impact neuroAIDS.

Keywords: Calcium, chemokines, buprenorphine, methadone, morphine, neuro-acquired immunodeficiency syndrome (neuroAIDS), opioid drug abuse, oxidative stress.
products [16, 29, 35-38]. In the case of Tat, morphine potentiates Tat-induced neuronal losses in striatal murine cell cultures [39], and exacerbates Tat toxicity in glial precursors and/or astroglia derived from mouse striatum [40]. Activating μ-opioid receptor (MOR)-expressing astroglia by morphine has been shown to modulate the central nervous system (CNS) response to pathogens such as HIV-1 proteins, resulting in synergistic increases in calcium mobilization [16, 28], increased production in oxyradicals [28, 41] and reduced survival of bystander neurons [28]. Importantly, synergy was lost if glia, but not neurons, lacked MOR, indicating that opiate interactions with HIV converge at the level of MOR-expressing glia [28]. Opiates acting through astroglial intermediates [16, 35-37, 42, 43] release chemokines such as CCL5/RANTES and CCL2/MCP-1 [16, 35-37, 43], which contribute to microglial overactivation and decrease the threshold for neuronal injury or death [36, 42, 44, 45]. In addition, it has been demonstrated that morphine and Tat co-administration synergistically increases ROS in MOR-expressing microglia [46]. Although the mechanism(s) by which morphine further triggers the inflammatory effects of Tat in microglia is unclear, morphine by itself was recently shown to enhance the release of proinflammatory cytokines and nitric oxide via a MOR–PKC-ε–Akt–ERK1/2 signaling pathway in activated microglia [47]. In turn, the viral proteins themselves may intrinsically modulate opioid receptor expression by astroglia and microglia [38], and throughout the CNS [26], suggesting a complex interplay of drug and viral protein actions on glia and neurons.

Considering that opiate abuse, HIV-1 infection and their comorbidity are global problems, an understanding of opiate addiction therapies in this context is of critical importance. Not only do addiction therapies limit the spread of infection by restricting needle sharing among injection drug users or via exchange of sex for drugs [48, 49], they also improve long-term health and “virological success” of drug abusers infected with HIV-1 [50-53]. Treatment protocols include the use of full MOR agonists such as methadone [54, 55] and levo-α acetylmethadol, or partial MOR agonists such as buprenorphine [53], or opioid-receptor antagonists such as naltrexone [48, 51]. Buprenorphine is a more recent, alternative approach to methadone—initially reported to have fewer side effects, less abuse liability, and greater safety because of its actions as a partial MOR agonist [56-59]. Despite reported advantages in treating opiate addiction [48, 49, 60-62], there is clear abuse potential with buprenorphine [63-65]. However, multiple reports suggest that supra-therapeutic doses of buprenorphine can have variable effects on neurogenesis [66, 67]. If administered prenatally, supraphysiological amounts of buprenorphine can cause depressive-like syndromes in rats [68] and reductions in myelin basic protein and the number of myelinated axons [69]. The “atypical” myelin patterns seen with prenatal exposure to higher concentrations of buprenorphine are attributed to buprenorphine’s actions as a partial antagonist at k- opioid receptors [70] and/or agonist actions at nociceptin/orphanin FQ (NOP or ORL1) receptors [69, 70]. Despite benefits from opiate addiction therapy in HIV-1-infected individuals, few studies have directly assessed the impact of methadone or buprenorphine-HIV-1 interactions in the CNS.

As past research indicates that opiate addiction treatments (e.g. methadone and buprenorphine) appear to limit the systemic consequences and spread of HIV-1 infection, it is hypothesized that opiate substitution therapies may intrinsically differ in their ability to potentiate HIV encephalitis (HIVE) and neuronal injury. Glia are the principal site of opiate drug abuse and Tat/HIV-1 interactions that trigger subsequent neuronal injury. Thus, the present study examined the effects of opiate drugs and drug therapies on isolated glia, and on neuron-glia cultures. Our goal was to assess the potential of opiate addiction medications to affect neuroinfectious or inflammatory outcomes related to neuroAIDS. First, we systematically examined neurotoxic effects of morphine, buprenorphine, and methadone on Tat-treated striatal spiny neurons cultured with mixed glia. Second, we examined the concentration-dependent effects of opiates on intracellular calcium ([Ca²⁺]) levels and on intracellular ROS formation in mixed-glia cultures. Third, we evaluated the effects of opiate drugs on chemokine production in combination with Tat protein. Elucidating the comparative pathophysiological effects of chronic exposure to morphine is critically important for understanding opiate addiction and for understanding how opiates contribute to neuroAIDS. Our findings suggest fundamental differences in the neuropathogenic potential of various opiate drug treatment options, with buprenorphine at lower concentrations actually reducing Tat-induced neurotoxicity. Effects on [Ca²⁺], ROS and chemokine production in mixed-glia appear to be less relevant for neuronal survival.

MATERIALS AND METHODS

Cell Culture

To assess the effects of opiate drugs and/or Tat on the survival of striatal spiny neurons, we co-cultured neurons with mixed glia enriched in astrocytes. This was followed by experiments using mixed-glia cultures to evaluate the pharmacological mechanisms of inflammation-related effects produced by opiate drugs and viral proteins on glial cells. All experiments were conducted in accordance with procedures reviewed and approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee (IACUC).

Mixed-glia cultures. Mixed-glia cultures were derived from striata of day 0-1 postnatal ICR (Charles River Laboratories, Charles River, MA) pups as previously described [16]. Striata were aseptically isolated, minced in media, incubated with trypsin/DNase (37 °C, 30 min, 2.5 mg/ml), triturated through a series of decreasing bore pipettes, and filtered twice through 100 μm and 40 μm pore nylon mesh. Growth medium favoring astroglial enrichment consisted of Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Invitrogen) supplemented with glucose (27 mM; Sigma), Na₂HCO₃ (6 mM; Invitrogen), HEPES (10 mM; GIBCO, Invitrogen) supplemented with glucose (27 mM; Sigma), Na₂HCO₃ (6 mM; Invitrogen), HEPES (10 mM; Invitrogen), and 10% (v/v) fetal bovine serum (FBS; JRH Biosciences or Hyclone, Logan, UT). Cells for each experiment were pooled from a single culture of two brains and plated at 50,000–150,000 cells/cm² in 96-well plates (Costar, Corning Life Sciences, Acton, MA). Mixed-glia cultures were grown for 10-14 days in vitro (DIV) at 37 °C.
in 5% CO₂/95% air at high humidity until 70–80% confluent. Previous research has shown that these cultures consist of approximately 91% astroglia and 8% microglia [28], mimicking the balance of glial types seen in the mouse striatum.

**Neuron-glia co-culture.** For the neurotoxicity studies, mixed-glia cultures were cultured first as described above and plated in poly-L-lysine-coated 24-well plates. Cultured striatal neurons from embryonic day 15-16 (E15-16) ICR embryos were prepared as described previously [39]. Briefly, striata from 4-6 embryos for each experiment were dissected free from the brain, minced, and incubated (30 min, 37 °C) with 10 ml trypsin (2.5 mg/ml; Sigma) and DNase (0.015 mg/ml; Sigma) in Neurobasal medium (NBM; Invitrogen) supplemented with B-27 additives (Invitrogen), L-glutamine (0.5 mM; Invitrogen), glutamate (25 μM; Sigma), and an antibiotic mixture (penicillin, streptomycin, amphotericin B; Invitrogen). Tissue was triturated, resuspended in 10 ml medium, filtered twice through a 70-μm pore nylon mesh. Cells (2.5 x 10⁵ neurons per well) were plated on a bedlayer of mixed glia grown in 10% FBS for 6 DIV. Neurons were allowed to mature for 6-8 DIV prior to treatment with Tat ± opiates. At 6-8 DIV, neurons have elaborated axons and dendrites, and express many characteristics of mature neurons, including relatively mature patterns of opioid receptor expression.

**Tat/Opiate Treatments**

Cells were treated with HIV-1 Tat_{Δ31-61} (ImmunoDiagnostics; clade B), which has a Cys 30-Cys 31 motif that is critical for exciting the NMDA receptor, not present in clade C Tat [71]. As such, clade B Tat acts to inhibit β-catenin signaling, a shared target of inflammatory factors, thereby promoting viral replication within astrocytes [72-75]. Negative controls were treated with HIV-1 Tat_{Δ31-61} (100 nM mutant Tat), a deletion mutation that lacks the excitotoxic core and basic domains of clade B Tat [76].

The opiate treatments, morphine sulfate, buprenorphine, and methadone were obtained from NIDA Drug Supply System (Rockville, MD). Naloxone (1.5 μM; Sigma) was used as a broad-spectrum opioid receptor antagonist and added 1 h before other treatments. Cell cultures were treated with Tat (100 nM) with time of exposure depending on the experimental assessment. For the concentration-response study, Tat treatment ranged from 0.001 nM to 100 nM. Similarly, depending on the experimental assessment, opiate treatments were added using various concentrations (ranging from 0.01 to 1000 nM) and added concurrently with Tat treatment. Details about the concentrations used and exposure durations are specified in the experimental assessment section for each individual assessment test.

**Assessment of Neuronal Viability in Neuron-Glia Co-Culture**

To study the neurotoxic effects of opiate drugs and Tat interactions, neuronal survival was measured by conducting repeated measures studies in neuron-glia-co-cultures. Computer-assisted, time-lapse imaging was used to track the same neurons for 48 h during treatment with equimolar concentrations of opiates (morphine 500 nM, buprenorphine ranging from 5 to 500 nM, and methadone 500 nM) and/or Tat (100 nM) exposure as has been previously described [77]. Briefly, 24-well plates were transferred to a heat insert MXX holder (PeCon Instruments, Houston, TX) and set on the scanning stage of a Zeiss Axio Observer Z.1 inverted microscope (Carl Zeiss Inc., Thornwood, NY). For each well, 6-10 non-overlapping fields were selected. A total of 8-10 individual medium spiny striatal neurons were identified in each field on the basis of their distinctive morphology in digital images. Time-lapse images of the same series of fields were recorded at 30 min intervals for 48 h after concurrent HIV-1 Tat and/or opiate treatment, using an automated, computer-controlled stage encoder and Axiovision 4.6 software (Carl Zeiss, Inc.). During the course of the experiment, cells were maintained in an XL SL environment incubator (PeCon) at 37 °C in 5% CO₂/95% air at high humidity. At the end of each experiment, we assessed all preselected neurons for viability in digital images taken at each time point during the entire treatment period. Death was assessed using rigorous morphological criteria, including the disintegration of neurites, as well as either the involution or complete fragmentation of the cell body. Neuronal death was confirmed by staining with ethidium monoazide [78]. To compare treatment effects on the survival of individual neurons, repeated assessments of the viability of individual neurons were analyzed at 4 h intervals throughout the 48 h experiment. Findings were recorded as the mean percentage of surviving neurons, relative to pretreatment numbers ± SEM from n = 3 independent experiments.

**Assessment of Intracellular Calcium ([Ca^{2+}]) in Mixed-Glial Cultures**

The dynamics of [Ca^{2+}]i transients in astrocytes is an important issue because calcium is established as an important second messenger and can trigger multiple sequences of events. Levels of [Ca^{2+}]i production in mixed-glia cultures were measured using a fluorescent microplate reader (NovoStar, BMG Labtech, Inc., Cary, NC). Mixed-glia cultures were plated on special UV-transparent, opaque-walled 96-well cell culture plates (Costar #3603, Corning Life Sciences, NY). Cells were loaded with 4 μM fura-2AM (Molecular Probes, Eugene, OR) for 45 min at 37 °C in Hank’s balanced salt solution (HBSS) supplemented with 10 mM HEPES buffer (pH 7.2). After three washes, the cells were further incubated for an additional 30 min at 37 °C to ensure de-esterification of the AM group of the fluorophore. To determine the effects of opiates and/or Tat on glial [Ca^{2+}]i, cultured mixed glia were pretreated for 30 min with Tat (100 nM) and/or morphine, buprenorphine, or methadone (ranging from 0.1 nM to 1000 nM). [Ca^{2+}]i data were acquired at 340/380 nm excitation and 510 nm emission wavelengths. Conversion to [Ca^{2+}]i was calculated according to an equation described previously [79]. Data represent percent of control values ± SEM from n = 6 independent experiments.

**Assessment of Intracellular Reactive Oxygen Species (ROS) Production in Mixed-Glial Cultures**

Glial-derived cellular toxins, including ROS production have been implicated as possible mediators of the opiate-
enhanced neurotoxicity driven by activation of MOR in astrocytes [16, 36-38, 41]. Because astroglia are a key site where opiates act to exacerbate the neurotoxic effects of HIV-1, we measured general ROS production in mixed-glial cultures. For drug assessments, we also looked at more specific hydrogen peroxide (H₂O₂) production.

Measurement of overall ROS production. Levels of ROS production were measured by using the indicator 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H₂DCFDA, Invitrogen, Carlsbad, CA), which is de-acetylated to dichlorofluorescein (DCF). Cells were loaded with 10 μM CM-H₂DCFDA in warm HBSS for 45 min according to the manufacturer’s protocol, then washed twice before treatments were applied. Two concentration-response experimental designs were used. In one design, cells were treated with Tat (100 nM) and opiates (morphine, buprenorphine, methadone) ranging in concentration from 0.1 nM to 1000 nM. In another design, Tat treatment ranged from 0.001 nM to 100 nM and morphine was held at 500 nM. After treatment, cells were incubated for 45 min at 37 °C before fluorescence was measured. Following 3 h incubation at 37 °C, 16 µl of stop solution (0.1 M glycine, pH 10.0) was added to each well, and the plates were washed twice before treatments were applied. Two concentration-response experimental designs were used. In one design, cells were treated with Tat (100 nM) and opiates (morphine, buprenorphine, methadone) ranging in concentration from 0.1 nM to 1000 nM. In another design, Tat treatment ranged from 0.001 nM to 100 nM and morphine was held at 500 nM. After treatment, cells were incubated for 45 min at 37 °C before fluorescence was measured at λ_ex = 485 nm and λ_em = 520 nm using a PHERAsstar FS (BMG Labtech, Inc., Cary, NC) microplate reader. ROS levels were normalized by cell viability to calculate the ROS/cell viability arbitrary unit ± SEM at the 45 min time point from n = 6 independent experiments.

Measurement of H₂O₂ production. To look at ROS in greater detail, levels of H₂O₂ production were assessed over a range of opiates concentrations as previously described [80]. Briefly, cells were washed once with warm HBSS, and then 50 μl of HBSS was added to each well, followed by 50 μl of control (HBSS) or opiates (ranging from 0.01 nM to 1000 nM; morphine, buprenorphine, methadone) and/or 100 nM Tat treatments. To each well, 100 μl of assay mix (200 μM homovanillic acid, 10 U/ml horseradish peroxidase, 2 mM homovanillic acid, 10 U/ml horseradish peroxidase, 2 mM HEPES, pH 7.5) with or without catalase (10,000 U/ml), was added. After treatment, cells were incubated for 3 h at 37 °C. Following 3 h incubation at 37 °C, 16 μl of stop solution (0.1 M glycine, pH 10.0) was added to each well, and the plates were read at λ_ex = 321 nm and λ_em = 421 nm using a PHERAsstar FS (BMG Labtech, Inc., Cary, NC) microplate reader. Results were calculated as catalase-inhibitable fluorescence and reported as percent of control values ± SEM at the 3 h time point from n = 9-12 independent experiments.

Assessment of Chemokine Release in Mixed-Glial Cultures

To examine whether opiate drugs and Tat in combination or alone can influence levels of released chemokines, the medium of striatal mixed-glial cultures was evaluated using a mouse cytokine assay system (Bio-Plex; Bio-Rad, Hercules, CA). Cells were incubated for 8 h with equimolar concentrations of opiates (500 nM, buprenorphine, or methadone) and/or Tat (100 nM). Three different chemokines were assayed simultaneously, including MIP-1β (or CCL4), RANTES (or CCL5), and MCP-1 (or CCL2). Calibration curves were prepared using sequential, four-fold dilutions of recombinant chemokine standards. Samples were measured and blank values were subtracted from all readings. Bio-Plex assays (Bio-Rad) were carried out directly in 96-well plates at room temperature, and protected from light, according to manufacturer’s directions. 50 μl of multiplex bead working solution was added to the plate and removed by vacuum filtration. 100 μl of Bio-Plex wash buffer was dispensed to each well and washed twice. Diluted samples or blanks were incubated (30 min, room temperature) with continuous shaking at 300 rpm. Beads were washed, incubated with detection antibody, and measured with streptavidin phycoerythrin. The fluorescence intensity of the beads was measured in a volume of 125 μl of Bio-Plex assay buffer. Data analyses were performed with Bio-Plex Manager software, version 4.0. Protein levels were measured in all samples using the bicinchoninic acid method (Pierce BCA Protein Assay Kit; Thermo Scientific, Rockford, IL). In samples where chemokine levels were below the detectable limit of the standard curve, data were replaced by the lowest value of the standard curve to avoid missing data points for analyses. The data were then transformed to indicate percent change values. Data represent the percentage of control values ± SEM from n = 6 independent experiments.

Statistical Analyses

Data were analyzed using analysis of variance (ANOVA) techniques (SYSTAT 11.0 for Windows, SYSTAT Inc.) followed by Duncan’s post-hoc analyses. For the within-subjects factors (i.e., neurotoxicity time-lapse studies), violations of compound symmetry were addressed by using the Greenhouse–Geisser (1959) degrees of freedom correction factor [81]. An alpha level of p < 0.05 was considered significant for all statistical tests used. Data are presented as the mean ± SEM.

RESULTS

Neurotoxicity of Opiates and/or Tat in Neuron-Glia Co-Culture

Effects of opiates (500 nM) and/or Tat (100 nM) exposure on neuronal survival were examined over a 48 h period (Fig. 1A). A repeated-measures ANOVA demonstrated a significant time x treatment interaction (pGG < 0.001). Neuronal survival significantly decreased over the 48 h period (time effect) for all Tat treatments and buprenorphine (pGG < 0.001), whereas morphine and methadone alone as well as control displayed no significant effect on neuronal survival over time. Exposure to Tat alone was intrinsically neurotoxic (p < 0.001 vs control), as was buprenorphine alone (p < 0.001 vs control). Importantly, all three opiates accelerated Tat neurotoxicity significantly above levels seen with Tat alone (p < 0.001).

As exposure to 500 nM buprenorphine alone was intrinsically neurotoxic, additional studies were conducted with lower concentrations of buprenorphine (5 and 50 nM, Fig. 1B). A repeated-measures ANOVA revealed a significant time x treatment interaction (pGG < 0.001). 50 nM and 500 nM buprenorphine resulted in a significant decrease in neuronal survival over the 48 h period (pGG < 0.05), but no time effect was noted for 5 nM buprenorphine alone. For combined treatment, only 500 nM buprenorphine accelerated
Time-dependent effects of opiate drugs and/or Tat on the survival of striatal spiny neurons cultured with mixed glia enriched in astrocytes. Results are the mean percentage of surviving neurons, relative to pretreatment number ± SEM from \( n = 3 \) experiments. (A) Neurons were assessed before and following exposure to equimolar concentrations of opiates (500 nM) and/or Tat (100 nM). Exposure to Tat and buprenorphine alone is intrinsically neurotoxic (*\( p < 0.05 \) vs control), whereas morphine and methadone alone have no significant effects on neuronal survival. Co-exposure to Tat and different opiates display neurotoxicity (*\( p < 0.05 \) vs control) and morphine and methadone accelerate Tat neurotoxicity significantly (*\( p < 0.05 \) vs Tat; †\( p < 0.05 \) vs corresponding drug alone). (B) Exposure to lower concentrations of buprenorphine alone or in combination with Tat indicate no significant effects for 5 nM buprenorphine, but for 50 nM and 500 nM (*\( p < 0.05 \) vs control). Buprenorphine with Tat exposure increases toxicity significantly (*\( p < 0.05 \) vs corresponding concentration alone). Further, 500 nM buprenorphine accelerates Tat neurotoxicity significantly (*\( p < 0.05 \) vs Tat), whereas 5 nM buprenorphine appears to protect against Tat neurotoxicity (*\( p < 0.05 \), buprenorphine 5 nM + Tat vs Tat).

Tat neurotoxicity significantly above levels seen with Tat alone (*\( p < 0.05 \)). Interestingly, 5 nM buprenorphine appeared to protect against Tat neurotoxicity at 44 h and 48 h following continuous exposure (*\( p < 0.05 \), buprenorphine 5 nM + Tat vs Tat). No significant difference was noted for 50 nM buprenorphine + Tat compared to Tat alone.

Opiate Drugs ± Tat (100 nM) on Intracellular Calcium \([\text{Ca}^{2+}]\), in Mixed-Glial Cultures

The effects of opiates and/or Tat (100 nM) exposure were examined on mixed glia by assessing \([\text{Ca}^{2+}]\) (Fig. 2). All three opiate drugs showed a concentration-dependent increase in \([\text{Ca}^{2+}]\), (*\( p < 0.05 \) for each opiate drug), as well as a significant main effect of Tat (*\( p < 0.05 \) for each opiate drug). For morphine and buprenorphine, Tat increased \([\text{Ca}^{2+}]\), similarly across different concentrations (Fig. 2A, B). In contrast, for methadone, Tat significantly increased \([\text{Ca}^{2+}]\), production only for the lower concentrations (< 100 nM), but not for 100 nM or 1000 nM methadone (Fig. 2C).
Effects of Opiate Drugs ± Tat (100 nM) on ROS in Mixed-Glial Cultures

To evaluate the effects of opiate drugs ± Tat on oxidative stress in mixed-glia, ROS production was assessed by DCF reactivity (Figs. 3, 4) and H2O2 production (Fig. 5).

DCF assessments. A significant concentration-dependent drug effect was noted for morphine (Fig. 3A, p < 0.05) and methadone (Fig. 3C, p < 0.05), but not buprenorphine (Fig. 3B). In combination with Tat, only morphine increased ROS across different concentrations (Fig. 3A, p < 0.05), but no Tat effect was noted for buprenorphine or methadone (Fig. 3B, C). When assessing different concentrations of Tat in combination with or without morphine (Fig. 4), only Tat concentrations ≤ 0.1 nM showed enhanced DCF values in combination with morphine. This suggests that lower Tat concentrations may have greater potential for interacting with opiate drugs.

H2O2 assessments. To evaluate the pharmacological mechanisms of inflammation-related effects produced by opiate drugs more in detail, full concentration effect curves for each opiate on the production of H2O2 were determined (Fig. 5). Morphine caused a significant concentration-dependent effect (p < 0.05) with 3-fold elevations in H2O2 at the highest concentration of morphine (Fig. 5A). Co-administering 1.5 μM naloxone significantly decreased the effect of 100 nM morphine on H2O2 production (p < 0.05). No significant concentration-dependent effect was noted for buprenorphine (Fig. 5B) or methadone (Fig. 5C). Naloxone (1.5 μM) significantly decreased H2O2 production at 100 nM for buprenorphine (p < 0.05). Importantly, a significant Tat effect was noted for H2O2 production compared to controls (p < 0.05).

Fig. (4). Concentration-dependent effects of Tat ± morphine (500 nM) on ROS formation measured by DCF in mixed-glia at 45 min following continuous exposure in vitro. Tat at concentrations ≥ 0.1 nM significantly increases ROS (*p < 0.05 vs control); while a non-toxic Tat deletion mutant (mTat) (100 nM) fails to increase ROS. Morphine exposure lowers the threshold for Tat-induced ROS production at lower doses of Tat (500 nM) (p < 0.05 vs corresponding Tat concentration alone). Results are the mean ± SEM from n = 6 experiments. Crt = control.

Effects of Tat and/or Buprenorphine and Methadone on Chemokine Production in Mixed-Glial Cultures

MIP-1β, RANTES, and MCP-1 production was assessed in striatal mixed-glia for Tat (100 nM) and/or buprenorphine and methadone (500 nM) at 8, 24, and 72 h (Fig. 6). The findings demonstrated similar effects at 8, 24, and 72 h and for this reason only the 8 h time is shown. Tat treatment alone significantly elevated RANTES from (p < 0.05). None of the opiates alone had a significant effect. Co-exposure to Tat and methadone significantly increased RANTES production compared to Tat alone (p < 0.05) and naloxone (1.5 μM) was able to reverse this effect.
neuronal death, but both exacerbate neurotoxicity in combination with Tat. This suggests that they may have potential negative side effects as opiate substitution therapies for HIV-1-infected patients. In contrast, buprenorphine at low concentrations was actually protective against Tat-induced neurotoxicity, although higher concentrations were toxic by themselves and exacerbated Tat-induced toxicity. The protective effect of 5 nM buprenorphine needs to be assessed more systematically in future studies. In patients receiving intravenous buprenorphine (0.3 mg) the buprenorphine plasma level has been shown to vary from 0.96 ± 0.15 ng/ml initially after 30 min to 0.10 ± 0.02 ng/ml after 13 h [82]. These levels are equivalent to 2 – 0.21 nM, indicating that 5 nM is more applicable to the clinical setting compared to 500 nM that shows neurotoxicity in our present study. This finding suggests basic differences in the actions of each opiate drug on neuronal injury induced by drug treatment alone.

Fig. (5). Concentration-dependent effects of different opiates on ROS assessed by \( \text{H}_2\text{O}_2 \) in a mixed-glial cultures. Results represent the percentage of control values and are the mean ± SEM from \( n = 9-12 \) experiments. (A) Morphine indicates a significant concentration-dependent response (\( \ast p < 0.01 \)) with a 3-fold elevation in \( \text{H}_2\text{O}_2 \) at the highest drug concentration. Naloxone (1.5 μM) significantly decreases \( \text{H}_2\text{O}_2 \) production at 100 nM (\( \ast p < 0.05 \) vs control). (B) No significant concentration-dependent effect is noted for buprenorphine. Naloxone (1.5 μM) significantly decreases \( \text{H}_2\text{O}_2 \) production at 100 nM (\( \ast p < 0.01 \) vs control). (C) No effects are noted for methadone. Importantly, Tat increases \( \text{H}_2\text{O}_2 \) production significantly (\( \ast p < 0.01 \) vs control).

**DISCUSSION**

Despite widespread use of, and benefits from, opiate addiction therapy in HIV-1-infected individuals, preclinical studies have not directly compared the relative effects of buprenorphine and methadone or their potential interactions with HIV-1 in the CNS. The findings of the present study indicate there are inherent pharmacological differences in the action of opiate addiction treatments on neuronal survival. Morphine and methadone by themselves cause minimal neuronal death, but both exacerbate neurotoxicity in combination with Tat. This suggests that they may have potential negative side effects as opiate substitution therapies for HIV-1-infected patients. In contrast, buprenorphine at low concentrations was actually protective against Tat-induced neurotoxicity, although higher concentrations were toxic by themselves and exacerbated Tat-induced toxicity. The protective effect of 5 nM buprenorphine needs to be assessed more systematically in future studies. In patients receiving intravenous buprenorphine (0.3 mg) the buprenorphine plasma level has been shown to vary from 0.96 ± 0.15 ng/ml initially after 30 min to 0.10 ± 0.02 ng/ml after 13 h [82]. These levels are equivalent to 2 – 0.21 nM, indicating that 5 nM is more applicable to the clinical setting compared to 500 nM that shows neurotoxicity in our present study. This finding suggests basic differences in the actions of each opiate drug on neuronal injury induced by drug treatment alone.

Fig. (6). Effects of buprenorphine or methadone ± Tat on chemokine production in mixed glia following 8 h of continuous exposure. Exposure to Tat alone significantly increases RANTES, MIP-1β, and MCP-1 production (\( \ast p < 0.05 \) vs control levels), while neither buprenorphine (500 nM) nor methadone (500 nM) alone affect the release of these three chemokines. In combination, methadone + Tat markedly increase the release of RANTES/CCL5, but not MIP-1β or MCP-1, beyond levels seen with Tat alone (\( \ast p < 0.05 \)) and the methadone-Tat interaction is prevented by naloxone (1.5 μM) (\( \ast p < 0.05 \) vs methadone + Tat). By contrast, Tat-induced chemokine release is unaffected by buprenorphine. Results are expressed as percent of control values and are the mean ± SEM from \( n = 6-12 \) experiments.

Why might morphine, methadone, and buprenorphine act differently? Several possibilities exist and all are likely to be operative to varying extents. First, similar to other G protein coupled receptors (GPCRs) [83-85], distinct opiate drugs can have differential actions in cells at MOR by coupling to one or more downstream effectors including Gα, Gβγ, and/or β-arrestin. Second, morphine, methadone, and buprenorphine
can activate MOR, δ-opioid (DOR), and κ-opioid (KOR), receptors. MOR and KOR stimulation can have opposing effects [86]. For example, MOR activation increases HIV-1 replication [87-90], while KOR downregulates HIV-1 expression in human microglia [87]. To add to the intricacy, morphine and methadone are both preferential MOR agonists, while buprenorphine has complex actions as a partial MOR agonist, a partial KOR antagonist [58, 91-94], and as a NOP agonist at high concentrations [69, 95, 96]. NOP activation has been considered as a possible underlying mechanism for the bell-shaped dose-response curve of buprenorphine [97]. Leukocytes including macrophages can express NOP [86] and buprenorphine preferentially activates NOP at high concentrations. Although the reported anti-inflammatory role for NOP activation in glia [98] and in spinal cord in a neuropathic pain model [99] seems contrary to the observed increases in neuronal death in the present study, it is uncertain to what extent HIV-1 Tat exposure might reprogram microglia/perivascular macrophages to uniquely respond to NOP stimulation. Third, GPCR heteromeric/oligomeric complexes may create novel actions that differ in cell-type and in context-specific manners [100]. MOR activation induces heterologous desensitization of CCR5, but not CXCR4 [101, 102]. Selectively targeting CCR5-MOR heteromeric complexes affects HIV entry via CCR5 HIV co-receptors [103, 104]. KOR activation can inhibit or trigger the release of specific proinflammatory cytokines [105], and KOR and CXCR4 can undergo cross-desensitization, suggesting additional potentially novel modes of buprenorphine action.

The finding that morphine exacerbates Tat neurotoxicity confirms prior studies [25, 39, 106], and we have now shown that equimolar concentrations of morphine, methadone, and buprenorphine show similar, neurotoxic interactions with Tat. As 100 nM Tat alone is significantly neurotoxic, the combinations of Tat and opiates may have reached a “ceiling effect” of maximal toxicity, which did not allow us to discriminate interactions between the opiates. The ability to vary opiate concentrations during Tat exposure allowed us to see the rate of neuronal losses (accelerated/decelerated). Further investigations will vary concentrations of Tat, using lower efficacious dosing [26] to further delineate the thresholds for opiate interactions on neuronal survival. The present study utilized Tat at 100 nM (and opiates at 500 nM) to permit comparisons with past experiments.

Although ROS production by microglia and astrocytes is implicated as a contributor to neurotoxicity [16, 36-38, 41], we did not find a clear-cut correlation since the three opiates by themselves were similar in their influence on ROS production in mixed glia. Alternatively, elevations in [Ca²⁺], in mixed-glia seemed to better coincide with neuronal losses. All three drugs alone caused marked increases in [Ca²⁺] at the highest concentrations, and while only buprenorphine alone caused neuronal losses—there was a tendency toward increased neuronal loss with morphine or methadone treatment and morphine-induced neuronal losses have occasionally been found [28]. We suspect that [Ca²⁺] dysregulation and heightened ROS in glia partially compromises neurons, but these events alone seem insufficient to trigger significant neuronal death. Alternatively, if the glial dysregulation coincides with an alternative insult—such as direct neuronal damage [26] or indirect insults such as other viral or cellular toxins—the compromised glia may be unable to provide sufficient metabolic/trophic support to prevent neuronal demise [26].

Besides increasing [Ca²⁺], mobilization [16] and the production of oxyradicals [41], HIV-1 proteins also significantly increase the release of chemokines, such as MCP-1 and RANTES from astrocytes [16, 36-38, 107]. RANTES, MCP-1, and MIP-1β have been demonstrated to be elevated in CNS tissues and/or the cerebrospinal fluid of individuals with HIV-1-associated neurocognitive disorders [32, 108-110]. Past research from our laboratory has already shown that morphine can dramatically exaggerate key astrogial responses to Tat [16]. Marked alterations in [Ca²⁺], homeostasis and an exaggerated release of the critical inflammatory chemokines MCP-1 and RANTES, and the cytokine IL-6 was reported for combined Tat and morphine treatment. This is in contrast to the present findings, where the combination of Tat and buprenorphine or methadone, did not exaggerate the release of MCP-1. Instead, Tat and methadone yielded an increase only in the release of RANTES, and Tat and buprenorphine treatment had no interactive effect. Astrocytes express CCR5 and CCR1, which are key receptor targets of RANTES [111], and RANTES is a potent activator of astrocytes. Findings that methadone or morphine [16], but not buprenorphine, in combination with Tat exacerbate the release of RANTES from mixed glia, suggest basic differences in the actions of each opiate drug on inflammatory responses induced by Tat proteins and additionally suggest that buprenorphine is intrinsically toxic to neurons in high concentrations.

Overall, our findings suggest that opiate drugs by themselves act similarly to modify proinflammatory ROS, [Ca²⁺], and the signature of the chemokine/cytokines released by glia. However, the ability to induce particular glial inflammatory factors does not necessarily coincide with the ability of each of these opiate addiction treatments to exacerbate Tat-induced neurotoxicity. Buprenorphine, in particular, shows the greatest range of interactive effects with Tat on neurotoxicity, presumably due to the drug’s complex actions at multiple non-MOR sites. At lower doses, buprenorphine actually limits the neurotoxicity of HIV-1 Tat. Thus, despite a potentially narrow therapeutic index, buprenorphine may have distinct advantages in the treatment of opiate addiction or pain management in HIV-1-infected patients.

**CONFLICT OF INTEREST**

The authors confirm that this article content has no conflict of interest.

**ACKNOWLEDGEMENTS**

We gratefully acknowledge Dr. Michelle Block for her help on the hydrogen peroxide assessment and support from the National Institute on Drug Abuse (NIDA R01 DA018633, R01 DA034231, K02 DA027374, and K99 DA033878).
REFERENCES

[1] Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8(1): 33-44.

[21] Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 2007; 27(14): 3703-3711.

[22] Bremennan DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988; 335(6191): 639-642.

[23] New DR, Ma M, Epstein LG, Nath A, Gelbard HA. Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 1997; 3(2): 168-173.

[24] Rappaport J, Joseph J, Croul S, Alexander G, Del Valle L, Amini S, Khalihi K. Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. J Leukoc Biol 1999; 65(4): 458-465.

[25] Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, Knapp PE, Hauser KF. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010; 177(3): 1397-1410.

[26] Fitting S, Knapp PE, Zou S, Marks WD, Bowers MS, Akbarali HI, Hauser KF. Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na+ influx, mitochondrial instability, and Ca2+ overload. J Neurosci 2014; 34(38): 12850-12864.

[27] Masvekar RR, El-Hage N, Hauser KF, Knapp PE. Morphine enhances HIV-1 Tat-mediated neuron death and delays recovery of injured neurites. PLoS One 2014; 9(6): e100196.

[28] Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE. Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia. Brain 2011; 134(Pt 12): 3613-3628.

[29] Hauser KF, Fitting S, Dever SM, Podhaizer EM, Knapp PE. Opiate drug use and the pathophysiology of neuroAIDS. Curr HIV Res 2012; 10(5): 435-452.

[30] Hauser KF, Knapp PE. Interactions of HIV and drugs of abuse: the importance of glia, neuronal progenitors, and host genetic factors. Int Rev Neurobiol 2014; 118: 231-313.

[31] Benos DJ, Hahn BH, Bubien JK, Ghosh SK, Mashburn NA, Chaklin MA, Shaw GM, Benveniste EN. Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: implications for AIDS dementia complex. Proc Natl Acad Sci U S A 1994; 91(1): 494-498.

[32] Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, Gallo RC, Major EO. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 1998; 95(6): 3117-3121.

[33] Nath A, Conant K, Chen P, Scott C, Major EO. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 1999; 274(24): 17098-17102.

[34] Kutsch O, Oh J, Nath A, Benveniste EN. Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 Tat in astrocytes. J Virol 2000; 74(19): 9214-9221.

[35] El-Hage N, Bruce-Keller AJ, Knapp PE, Hauser KF. CCL5/RANTES gene deletion attenuates opioid-induced increases in glio CCL2/MCP-1 immuneactivity and activation in HIV-1 Tat-exposed mice. J Neuroimmune Pharmacol 2008; 3(4): 275-285.

[36] El-Hage N, Wu G, Wang J, Ambuthi N, Knapp PE, Reed JL, Bruce-Keller AJ, Hauser KF. HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 2006; 53(2): 132-146.

[37] El-Hage N, Bruce-Keller AJ, Yavkuleva T, Bazov I, Bakalkin G, Knapp PE, Hauser KF. Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca2+]i, NF-kB trafficking and transcription. PLoS One 2008; 3(2): e4093.

[38] Turchan-Cholewo J, Dimayuya FO, Ding Q, Keller JN, Hauser KF, Knapp PE, Bruce-Keller AJ. Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res 2008; 86(9): 2100-2110.

[39] Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF. Synergistic neurotoxicity of opioids and human...
immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 2001; 102(3): 555-563.

Khurdayan VK, Buch S, El-Hage N, Lutz SE, Goebel SM, Singh IN, Knapp PE, Turchan-Cholewo J, Nath A, Hauser KF. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci 2004; 19(12): 3171-3182.

Hauser KF, Harris-White ME, Jackson JA, Opanashuk LA, Carney JM. Opioids disrupt Ca2+ homeostasis and induce carbonyl oxyradical production in mouse astrocytes in vitro: transient increases and adaptation to sustained exposure. Exp Neurol 1998; 151(1): 70-76.

Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, Persidsky Y, Volsky DJ, Knapp PE. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007; 100(3): 567-586.

El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE, Hauser KF. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 2006; 178(1-2): 9-16.

Hauser KF, El-Hage N, Buch S, Nath A, Tyor WR, Bruce-Keller AJ, Knapp PE. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol 2006; 1(1): 98-105.

Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, Bruce-Keller AJ, Knapp PE. Molecular targets of opioid drug abuse in neuroAIDS. Neurotox Res 2005; 8(1-2): 63-80.

Turchan-Cholewo J, Dimayuga FO, Gupta S, Keller DJ, Knapp PE, Hauser KF, Bruce-Keller AJ. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 2009; 108(1): 202-215.

Merigli S, Gessi S, Varani K, Fazzi D, Stefanelli A, Borea PA. Morphine mediates a proinflammatory phenotype via mu-opioid receptor-PKC- Akt-ERK1/2 signaling pathway in activated microglial cells. Biochem Pharmacol 2013; 86(4): 487-496.

Khalas J, Voci F, Altice F, Filli G, Miller V. Buprenorphine and HIV primary care: new opportunities for integrated treatment. Clin Infect Dis 2006; 43 Suppl 4: S169-172.

Altice FL, Sullivan LE, Smith-Rohrbarg B, Basu S, Stancill S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis 2006; 43 Suppl 4: S178-183.

Roux P, Carrieri MP, Villes V, Della Monica P, Poizot-Martin I, Ravaux I, Spire B. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103(11): 1828-1836.

Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005; 315(3): 1320-1330.

Petit AS, Desroches R, Bennett SA. The opiate analog buprenorphine decreases proliferation of adult hippocampal neuroblasts and increases survival of their progeny. Neuroscience 2012; 200: 211-222.

Wu CC, Hong CJ, Chen CH, Chen WY, Chang CY, Pan HC, Liu SL, Chen CJ. Prenatal buprenorphine exposure decreases neurogenesis in rats. Toxicology letters 2014; 225(1): 92-101.

Hung CJ, Wu CC, Chen WY, Chang CY, Kuan YH, Pan HC, Liu SL, Chen CJ. Depression-like effect of prenatal buprenorphine exposure in rats. PLoS One 2013; 8(12): e82262.

Eschenroeder AC, Nestel-Laborde AA, Sanchez ES, Robinson SE, Sato-Bigbee C. Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of mu-opioid and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy. Glia 2012; 60(1): 125-136.

Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C. Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 2008; 56(9): 1017-1027.

Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, Shankar SK, Mahadevan A, Satishchandra P, Nath A. NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 2008; 28(47): 12190-12198.

Van de Warrenburg BP, Bemelmans C, Bazov I, Artemenko KA, Yakovleva T, Dooijes D, Buch SK, Khurdayan VK, Lutz SE, Knapp PE, Hauser KF. Potential for abuse of buprenorphine in opioid-addicted youth: a randomized trial. JAMA 2008; 300(17): 2003-2011.

Carriero MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43 Suppl 4: S197-215.

Lunn PJ, Tulsky JP. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep 2006; 3(4): 195-204.

Sullivan LE, Filli G. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005; 41(6): 891-896.

Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med 2005; 353(17): 1863-1865.

Spicer KA. Buprenorphine: a primer for emergency physicians. Annals of emergency medicine 2004; 43(5): 580-584.

Comer SD, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005; 315(3): 1320-1330.

Carriero MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43 Suppl 4: S197-215.
Grynkwicz G, Potenie M, Tsien RY. A new generation of Ca^2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260(6): 3440-3450.

Levesque S, Taetsch T, Lull ME, Kodavanti U, Stadler K, Wagner A, Johnson JA, Duke L, Kodavanti P, Surace MJ et al. Diesel exhaust activates & primes microglia: air pollution, neuroinflammation, & regulation of dopaminergic neurotoxicity. Environ Health Perspect 2011; 119(8): 1149-55.

Greenhouse SW, Geisser S. On methods in the analysis of profile data. Psychometrika 1959; 24: 95-112.

Bullingham RE, McQuay HJ, Porter RJ, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13(5): 665-673.

Gainetdinov RR, Premont RT, Bohn LM, LeKowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004; 27: 107-144.

Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 2008; 153 Suppl 1: S379-388.

Zheng H, Chu J, Qiu Y, Loh HH, Law PY. Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci U S A 2008; 105(27): 9421-9426.

Finley MJ, Happel CM, Kaminsky DE, Rogers TJ. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cellular immunology 2008; 252(1-2): 146-154.

Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, Bu DF, Archer S, Bidlack JM, Peterson PK. Opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci U S A 1996; 93(15): 8051-8056.

Chao CC, Gekker G, Lokensgard JR, Heyes MP, Peterson PK. U50,488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression. Neuropharmacology 2000; 39(1): 150-160.

Peterson PK, Sharp BM, Gekker G, Jackson B, Balfour HH, Jr. Opiates, human peripheral blood mononuclear cells, and HIV. Adv Exp Med Biol 1991; 288: 171-178.

Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH, Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cultures. AIDS 1990; 4(9): 869-873.

Boothby LA, Doering PL. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm 2007; 64(3): 266-272.

George S, Day E. Buprenorphine in the treatment of opioid dependence. Br J Hosp Med (Lond) 2007; 68(11): 594-597.

Orman JS, Keating GM. Buprenorphine/naloxone: a review of its involvement in opioid dependence. Br J Hosp Med (Lond) 2007; 68(11): 594-597.

Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH, Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cultures. AIDS 1990; 4(9): 869-873.

Wakhlu S. Buprenorphine: a review. J Opioid Manag 2009; 5(1): 59-64.

Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid on the nociceptin/OFQ receptor. Peptides 2000; 21(7): 1141-1146.

Wnendt S, Kruger T, Janocha E, Hildebrandt D, Engblinger W. Agonistic effect of buprenorphine on the nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol 1999; 56(2): 334-338.

Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Current neuropharmacology 2004; 2(4): 395-402.

Fitting et al.